Log In
Monday 24th June 2019

NICE approves Pazopanib for kidney cancer

24th February 2011

The National Institute for Health and Clinical Excellence has approved a new treatment for kidney cancer.

The NHS drugs advisory body has recommended Pazopanib as a first-line treatment for those with advanced kidney cancer in certain circumstances. It has also been recommended for patients who have not previously had cytokine therapy and either remain active or only struggle with strenuous activity. Manufacturer GlaxoSmithKline has agreed a discount on the list price with a possible future rebate linked to the outcome of a clinical trial.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2019